TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Inclusion Criteria: * Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor * Documented history of carcinoid syndrome and currently experiencing ≥4 bowel movements per day during the Run-in period * Currently receiving stable-dose somatostatin analog (SSA) therapy * Minimum dose of long-acting release (LAR) or depot SSA therapy * Octreotide LAR at 30 mg every 4 weeks * Lanreotide Depot at 120 mg every 4 weeks * Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose * Ability and willingness to provide written informed consent Exclusion Criteria: * Presence of diarrhea attributed to any condition(s) other than carcinoid syndrome * Karnofsky Performance status ≤60% * Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors \<4 weeks prior to Screening, or hepatic embolization, radiotherapy, radiolabelled SSA, and/or tumor debulking \<12 weeks prior to Screening * History of short bowel syndrome (SBS) * Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study * Previous exposure to telotristat etiprate